NeuroTimone Facility (PFNT)

The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.

News

  1. New grant for NPD team!

    We are pleased to announce that our team has obtained a FRM "2024 prematuration" grant for a project in collaboration with BBB team and Vect-Horus.

    The funding will start 1st of November for one year and will allow us to pursue our scientific research on MT5-MMP and its role in Alzheimer disease using in this particular project vectorised mimetic peptides as a potential therapeutical approach.

  2. Société de Neuroendocrinologie 2024 à Nice

    Maud Gratuze (SynapTau team) has been invited to the SNE 2024 in Nice to give a presentation titled "Unveiling the Brain's Chubby Secrets: Disrupted Cholesterol and Lipid Metabolism in Alzheimer's Disease" at a symposium on Alzheimer's disease.

  3. GlioME Team: another new paper in Cell Death & Disease!

    A new article from the GlioME Team has just been published in Cell Death and Disease: SMAC mimetic drives microglia phenotype and glioblastoma immune microenvironment.

  4. GlioME team and PETRA"TECH" platform: a new paper is out in Neuro-Oncology!

    Because generation of patient avatar for preclinical therapeutic development is critically needed in neuro-oncology, the GlioME team in collaboration with the PETRA"TECH" platform developed an easy method to generate tumoroids from primary and metastatic brain tumors, including a dedicated 3D spatial analysis workflow for drug development.

  5. Emeline Tabouret from the GlioME Team discussed data from trials during the proffered paper session – CNS tumours at the ESMO Congress 2024 (13-17 September, Barcelona, Spain)
  6. ERC Starting Grant for the SynapTau team

    Maud, Chiara, and Matthew (SynapTau team) are happy to announce the award of an ERC Starting Grant for the team, with the project set to begin in January 2025. The ERC project "SynApoE" aims to characterize how ApoE4 controls synaptic degeneration in Alzheimer's disease.

    We invite you to celebrate this great news on September 23rd, during Maud's HDR celebration.

    We look forward to sharing this moment with you!

  7. NeuroCyto team in Science: the unique architecture of axonal endocytosis

    We’re over the moon to see our latest work with Stéphane Vassilopoulos and his team published in Science. Check out how we reveal the unique architecture of clathrin-coated pits and endocytosis at the axon initial segment!

  8. INP teams attending Canceropole 11th Annual Seminar

    Comme chaque année les équipes 8, 9 et 10 de l’INP ont participé au Séminaire Annuel du Canceropôle qui se tenait au Palais des Congrès de Saint-Raphaël les 4 et 5 juillet 2024.

Pages

INP in numbers

  • 126 members
  • 44 researchers
  • 48 research assistants
  • 12 post-docs
  • 11 PhD

 

Filled position: Post-doctoral position for a super-resolution microscopy enthusiast in the NeuroCyto lab (C. Leterrier)

The NeuroCyto lab is looking to hire a postdoctoral fellow for an exciting project at the interface of microscopy and neuronal cell biology.
Deadline for application: January 15th, 2023. Starting date (flexible): April 2023.

About the position and project

English

New grant for NPD team!

We are pleased to announce that our team has obtained a FRM "2024 prematuration" grant for a project in collaboration with BBB team and Vect-Horus.

The funding will start 1st of November for one year and will allow us to pursue our scientific research on MT5-MMP and its role in Alzheimer disease using in this particular project vectorised mimetic peptides as a potential therapeutical approach.

Undefined

GlioME team and PETRA"TECH" platform: a new paper is out in Neuro-Oncology!

Because generation of patient avatar for preclinical therapeutic development is critically needed in neuro-oncology, the GlioME team in collaboration with the PETRA"TECH" platform developed an easy method to generate tumoroids from primary and metastatic brain tumors, including a dedicated 3D spatial analysis workflow for drug development.

Undefined

Emeline Tabouret from the GlioME Team discussed data from trials during the proffered paper session – CNS tumours at the ESMO Congress 2024 (13-17 September, Barcelona, Spain)

Three presentations at the ESMO Congress 2024 (Barcelona, 13–17 September) reported on therapies designed to stimulate or boost the body’s antitumour immune response in the management of aggressive, high-grade gliomas, which typically carry a poor prognosis.

Emeline Tabouret from GlioME Team discussed these data during the proffered paper session – CNS tumours reported here.

 

English

ERC Starting Grant for the SynapTau team

Maud, Chiara, and Matthew (SynapTau team) are happy to announce the award of an ERC Starting Grant for the team, with the project set to begin in January 2025. The ERC project "SynApoE" aims to characterize how ApoE4 controls synaptic degeneration in Alzheimer's disease.

We invite you to celebrate this great news on September 23rd, during Maud's HDR celebration.

We look forward to sharing this moment with you!

Undefined

Next seminars

18 Oct 2024 14:30

Team 11: Dr. Michael Koslowski

Amphi 7

titre de la présentation : First results from the EPIsoDE trial, a phase IIb study to assess efficacy and safety of psilocybin for treatment-resistant depression

 

un court abstract:

Psilocybin is being extensively studied for treating depressive disorders, with promising results. The German EPIsoDE trial

(EudraCT: 2019-003984-24; NCT04670081) is a randomized, double-blind, placebo-controlled study comparing high-dose (25 mg)

and low-dose (5 mg) psilocybin with an active placebo (100 mg nicotinamide) in patients with treatment-resistant depression (TRD).

Between July 2021 and February 2024, 144 patients were treated at two sites (Charité Berlin and CIMH Mannheim).

Participants were assigned to one of four treatment arms, receiving one or two doses of psilocybin, with all patients receiving

at least one high dose for ethical reasons. This talk will present the study’s rationale and early results, along with insights

from treating this vulnerable TRD population. Challenges and lessons from the trial will be discussed, with implications for future

research and clinical practice.

24 Oct 2024 14:30

equipe 4 guest candidate de post-doc (Imane Charmarke Askar)

Salle 52 5e étage aile rouge

Seminaire interne ouvert à l'INP

Title : From the identification of a molecular signature of multiple sclerosis to the validation of the pro-differentiating and remyelinating effect of lumican

Partners